Charles River Laboratories Int (CRL) Share Price Declined While Hodges Capital Management Has Trimmed Stake; Scorpio Tankers (STNG) Share Price Declined While Solus Alternative Asset Management LP Has Upped by $4.07 Million Its Holding

April 24, 2018 - By Richard Conner

Scorpio Tankers Inc. (NYSE:STNG) Logo

Christopher Pucillo increased its stake in Scorpio Tankers Inc (STNG) by 19.23% based on its latest 2017Q4 regulatory filing with the SEC. Solus Alternative Asset Management Lp bought 1.36M shares as the company’s stock declined 36.71% with the market. The hedge fund run by Christopher Pucillo held 8.42 million shares of the marine transportation company at the end of 2017Q4, valued at $25.68M, up from 7.06 million at the end of the previous reported quarter. Solus Alternative Asset Management Lp who had been investing in Scorpio Tankers Inc for a number of months, seems to be bullish on the $785.96 million market cap company. The stock decreased 0.42% or $0.01 during the last trading session, reaching $2.37. About 2.01 million shares traded. Scorpio Tankers Inc. (NYSE:STNG) has declined 52.61% since April 24, 2017 and is downtrending. It has underperformed by 64.16% the S&P500.

Hodges Capital Management Inc decreased its stake in Charles River Laboratories Int (CRL) by 40.92% based on its latest 2017Q4 regulatory filing with the SEC. Hodges Capital Management Inc sold 35,995 shares as the company’s stock declined 1.14% with the market. The institutional investor held 51,961 shares of the health care company at the end of 2017Q4, valued at $5.69 million, down from 87,956 at the end of the previous reported quarter. Hodges Capital Management Inc who had been investing in Charles River Laboratories Int for a number of months, seems to be less bullish one the $5.01 billion market cap company. The stock decreased 1.98% or $2.11 during the last trading session, reaching $104.41. About 88,684 shares traded. Charles River Laboratories International, Inc. (NYSE:CRL) has risen 21.28% since April 24, 2017 and is uptrending. It has outperformed by 9.73% the S&P500.

Among 10 analysts covering Scorpio Tankers Inc. (NYSE:STNG), 9 have Buy rating, 0 Sell and 1 Hold. Therefore 90% are positive. Scorpio Tankers Inc. had 36 analyst reports since July 21, 2015 according to SRatingsIntel. The rating was upgraded by UBS to “Buy” on Monday, November 13. The firm has “Underperform” rating given on Tuesday, January 17 by Bank of America. Jefferies maintained Scorpio Tankers Inc. (NYSE:STNG) on Monday, October 30 with “Buy” rating. The stock has “Buy” rating by Bank of America on Monday, March 19. Jefferies maintained the stock with “Buy” rating in Monday, July 3 report. Stifel Nicolaus maintained it with “Buy” rating and $5.0 target in Wednesday, January 24 report. The stock of Scorpio Tankers Inc. (NYSE:STNG) has “Buy” rating given on Wednesday, July 27 by Jefferies. As per Monday, August 28, the company rating was maintained by Stifel Nicolaus. Stifel Nicolaus maintained the shares of STNG in report on Tuesday, November 28 with “Buy” rating. The stock of Scorpio Tankers Inc. (NYSE:STNG) has “Buy” rating given on Tuesday, May 30 by Jefferies.

Among 20 analysts covering Charles River Laboratories (NYSE:CRL), 8 have Buy rating, 1 Sell and 11 Hold. Therefore 40% are positive. Charles River Laboratories had 48 analyst reports since August 3, 2015 according to SRatingsIntel. Gabelli initiated the stock with “Buy” rating in Tuesday, April 26 report. The stock has “Buy” rating by Jefferies on Monday, October 9. RBC Capital Markets maintained Charles River Laboratories International, Inc. (NYSE:CRL) rating on Thursday, November 2. RBC Capital Markets has “Hold” rating and $110.0 target. The firm has “Buy” rating by Robert W. Baird given on Thursday, August 31. Credit Suisse initiated Charles River Laboratories International, Inc. (NYSE:CRL) rating on Tuesday, June 21. Credit Suisse has “Neutral” rating and $84 target. The firm has “Sell” rating by UBS given on Tuesday, September 6. The rating was maintained by Jefferies on Monday, November 13 with “Buy”. The firm earned “Underweight” rating on Friday, May 20 by Barclays Capital. Barclays Capital upgraded Charles River Laboratories International, Inc. (NYSE:CRL) rating on Wednesday, November 30. Barclays Capital has “Equal Weight” rating and $77 target. As per Friday, August 28, the company rating was maintained by William Blair.

Hodges Capital Management Inc, which manages about $2.29B and $1.36 billion US Long portfolio, upped its stake in Cinemark Holdings Inc (NYSE:CNK) by 120,725 shares to 305,447 shares, valued at $10.64M in 2017Q4, according to the filing. It also increased its holding in Werner Enterprises Inc (NASDAQ:WERN) by 30,695 shares in the quarter, for a total of 391,055 shares, and has risen its stake in Air Transport Services Group I (NASDAQ:ATSG).

Since January 2, 2018, it had 0 buys, and 21 selling transactions for $10.85 million activity. $396,899 worth of Charles River Laboratories International, Inc. (NYSE:CRL) was sold by Smith David Ross. Barbo William D sold $250,741 worth of Charles River Laboratories International, Inc. (NYSE:CRL) on Wednesday, February 21. $1.08M worth of Charles River Laboratories International, Inc. (NYSE:CRL) shares were sold by Girshick Birgit. 2,872 Charles River Laboratories International, Inc. (NYSE:CRL) shares with value of $312,172 were sold by CHUBB STEPHEN D. The insider MILNE GEORGE M JR sold 7,740 shares worth $890,100.

Analysts await Charles River Laboratories International, Inc. (NYSE:CRL) to report earnings on May, 10 before the open. They expect $1.26 EPS, down 2.33% or $0.03 from last year’s $1.29 per share. CRL’s profit will be $60.41M for 20.72 P/E if the $1.26 EPS becomes a reality. After $1.40 actual EPS reported by Charles River Laboratories International, Inc. for the previous quarter, Wall Street now forecasts -10.00% negative EPS growth.

Charles River Laboratories International, Inc. (NYSE:CRL) Institutional Positions Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.